Protocol Ledger

NCT07365995 · Phase III · RECRUITING

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Interventional Phase III clinical trial protocol NCT07365995 sponsored by BioNTech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-22 Enrollment: 736 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07365995
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)736 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07365995
Protocol FieldVerified Registry Value
NCT IdentifierNCT07365995
Consolidated Lead SponsorBioNTech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment736 participants (ESTIMATED)
Registered Start Date2026-04-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07365995
Hospital Research SiteLocationSite Profile
Florida Cancer Specialists (Fort Myers)Fort Myers, FLOpen Hospital Dossier ->
Florida Cancer Specialists (Saint Petersburg)Saint Petersburg, FLOpen Hospital Dossier ->
Florida Cancer Specialists (West Palm Beach)West Palm Beach, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI